Gliknik Announces Dosing of First Patient in Phase 2 Trial Targeting Prevention of Recurrence of High-Risk Oral Cavity Cancer
Monday, August 28, 2017
–Trial to Assess Effectiveness and Safety of Biropepimut-S (GL-0817) in the Prevention of Recurrence of Squamous Cell Cancer of the Oral Cavity in Patients at High Risk of Recurrence after Successful Initial Treatment –
BALTIMORE, Maryland, August 28, 2017 – Gliknik Inc. today announced that clinicians have enrolled and dosed the first of 80 patients in the company’s phase 2 clinical trial assessing the efficacy and safety of biropepimut‐S (GL-0817), an immunomodulatory therapeutic targeting the prevention of recurrence of squamous cell cancer of the oral cavity in patients at high risk of recurrence after surgery, chemotherapy, and radiation.
“We are pleased to enroll the first patient in this phase 2 trial of biropepimut-S, which will further our understanding of the potential role of this advanced-design cancer vaccine with immune enhancing adjuvants in high-risk oral cavity cancer,” said Jeff Herpst, Senior Director of Clinical Development at Gliknik.
Click here to read the rest of the story.